Repeat length as a key determinant for disease severity and antisense oligonucleotide activity in myotonic dystrophy type 1
Open Access
- 2 June 2025
- journal article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 33 (3) , 101502
Abstract
No abstract availableKeywords
Funding Information
- Institut de Myologie
- Prinses Beatrix Spierfonds (W.OR18\u201306)
- Prinses Beatrix Spierfonds (W.OR19-07)
This publication has 72 references indexed in Scilit:
- Myotonic dystrophy protein kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1Cellular Signalling, 2008
- Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansionsNeurology, 2006
- Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1Neurology, 2004
- Loss of the Muscle-Specific Chloride Channel in Type 1 Myotonic Dystrophy Due to Misregulated Alternative SplicingMolecular Cell, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Decreased levels of myotonic dystrophy protein kinase (DMPK) and delayed differentiation in human myotonic dystrophy myoblastsNeuromuscular Disorders, 2001
- Characterization of a monoclonal antibody panel shows that the myotonic dystrophy protein kinase, DMPK, is expressed almost exclusively in muscle and heartHuman Molecular Genetics, 2000
- Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytesAnnals of Neurology, 1994
- Larger expansions of the CTG repeat in muscle compared to lymphocytes from patients with myotonic dystrophyHuman Molecular Genetics, 1993
- Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family memberCell, 1992